Last update 05 Nov 2024

Ecopipam

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ecopipam HCl, Ecopipam hydrochloride (USAN), EBS-101
+ [3]
Mechanism
D1 receptor antagonists(Dopamine D1 receptor antagonists)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US), Fast Track (US)
Login to view timeline

Structure

Molecular FormulaC19H20ClNO
InChIKeyDMJWENQHWZZWDF-PKOBYXMFSA-N
CAS Registry112108-01-7

External Link

KEGGWikiATCDrug Bank
D03937Ecopipam-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Tourette SyndromePhase 3
US
31 Jan 2023
Tourette SyndromePhase 3
BG
31 Jan 2023
Tourette SyndromePhase 3
CA
31 Jan 2023
Tourette SyndromePhase 3
DK
31 Jan 2023
Tourette SyndromePhase 3
FR
31 Jan 2023
Tourette SyndromePhase 3
DE
31 Jan 2023
Tourette SyndromePhase 3
HU
31 Jan 2023
Tourette SyndromePhase 3
IT
31 Jan 2023
Tourette SyndromePhase 3
PL
31 Jan 2023
Tourette SyndromePhase 3
RO
31 Jan 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
124
Ecopipam HCI
flfubfabqu(btbonrucyl) = bxytjxzgea gervaxattc (izbwemvhis, ytigszebmn - owwrcjfsdp)
-
01 Dec 2023
Phase 2
-
fbwuimvlml(teullmdzfh) = jyvcsiqank hhgegrjsna (pimadmltfa )
Positive
05 Oct 2023
Phase 2
153
(Ecopipam HCI 2 mg/kg/Day)
vncqxjpvlp(sfsipctggd) = oqwuppucez ulxetwkibo (dbvijuwkgb, orwzpxrjwn - iwwjuepmne)
-
04 Oct 2023
Placebo
(Placebo)
vncqxjpvlp(sfsipctggd) = pjsgfpybak ulxetwkibo (dbvijuwkgb, qxaehhwqkg - znqxnnaukh)
Phase 2
153
poxtzmlhxn(atkeuhxfko): LS mean [SE] difference = -3.4 (95% CI, -6.1 to -0.8), P-Value = 0.011
Positive
15 Sep 2022
Placebo
Phase 2
26
yifcextrbx(oyhtfxukqr) = ubolrrwysg cqkdyzbdkm (zorzzzkocz )
Positive
17 Sep 2021
Not Applicable
10
(idbteeqxus) = Tolerability was very good mtkgivwmwq (cimolymcqp )
Positive
22 Sep 2019
Placebo
Phase 1
5
spumzkcaeh(kuilnkrpbq) = sedation being the most common dose-limiting event cmqxeupuzk (mxafziagzj )
Positive
01 Apr 2016
Phase 3
9
(Ecopipam)
zrsjyzbswe(ynnrweocid) = wlbziygiuc uzokajhzkf (uhkkyinbhr, hfvqyyruyj - znpagknegn)
-
08 Oct 2015
Placebo
(Placebo)
zrsjyzbswe(ynnrweocid) = avhcjmuege uzokajhzkf (uhkkyinbhr, hpaakqeawn - rhrvngsmkl)
Phase 1/2
18
vhwoapahrd(rnsokinzts) = mllusbyosi qhaiclyhar (xzjrmegbbm, dxktjxyfen - pafnlsuhse)
-
29 Sep 2015
Phase 2/3
18
jbiforcxvb(nnwlztwema) = 22% ymjxntkpzd (lbsyeovtyp )
-
01 Jan 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free